Get the Stockscreener App
9.28
10.34%
-1.07
Recursion Pharmaceuticals Inc stock is traded at $9.28, with a volume of 31.23M.
It is down -10.34% in the last 24 hours and up +34.88% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$10.35
Open:
$10.38
24h Volume:
31.23M
Relative Volume:
1.53
Market Cap:
$3.63B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-5.9871
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-11.87%
1M Performance:
+34.88%
6M Performance:
+21.78%
1Y Performance:
-24.98%
1-Day Range:
$9.15
$10.60
1-Week Range:
$9.15
$12.36
52-Week Range:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
9.28 | 3.63B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA's AI Favorite? - MSN
Top Biotech Stocks To ConsiderFebruary 20th - MarketBeat
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? - MarketBeat
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Biotech Stocks Worth WatchingFebruary 15th - MarketBeat
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025 - MSN
Recursion Pharma Accelerator Steps In to Fill Some of the Funding Gap Amid NIH Tumult - MedCity News
Backed by Recursion CEO, Altitude Lab venture aims to fill gap from NIH cuts - MM+M Online
10 Best Performing Healthcare Stocks So Far in 2025 - Insider Monkey
Recursion CEO launches pre-seed fund in response to NIH cuts - BioPharma Dive
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City - The Manila Times
Can This New Biotech Fund Save 1,500 Startups Hit by SBIR Changes? - StockTitan
Could this Nvidia-backed growth stock be a millionaire-maker at $10? - Yahoo Finance UK
Recursion CEO: Publicly funded research built the biopharma industry. Now it needs our help - STAT
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday - MSN
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 - MSN
5 Stocks Jensen Huang’s Company is Betting On - Insider Monkey
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock - MSN
Altitude Lab's Startup Portfolio Hits $154M Milestone: Inside the Biotech Incubator's Success Story - StockTitan
25 Top AI Stocks That Could Boost Your Portfolio - The Motley Fool
SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge - NewsBreak
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype - MSN
Best Biotech Stocks To Keep An Eye OnFebruary 14th - MarketBeat
Promising Mid Cap Stocks To Add to Your WatchlistFebruary 16th - MarketBeat
The Rise of Recursion Pharmaceuticals: A Biotech Stock on the Move - RagingBull
Promising Biotech Stocks To Follow NowFebruary 17th - MarketBeat
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week - MSN
SoftBank reports new stakes in PacBio, Recursion Pharmaceuticals - MSN
Recursion Pharmaceuticals (NASDAQ: RXRX) Surges Nearly 24% as Nvidia Retains Stake – market - HPBL
Recursion Pharmaceuticals Stock Soars as Nvidia Maintains Stake – A Vote of Confidence? – market - HPBL
Recursion Pharmaceuticals (RXRX) Sees Institutional Investors Adjust Positions Amid Market Volatility - HPBL
Institutional Investors Bet Big on Recursion Pharmaceuticals (RXRX) Amid Growing Biotech Interest - HPBL
Why Recursion Pharmaceuticals (RXRX) Skyrocketed 23.88% on Friday – market - HPBL
Recursion Pharmaceuticals (RXRX): A Biotech Stock Outpacing the Market with Explosive Growth - HPBL
Recursion Pharmaceuticals (RXRX) Stock Surges 15%: Nvidia’s Vote of Confidence Sparks AI Biotech Rally - HPBL
Recursion Pharmaceuticals Stock Surges 15.8% as Nvidia Retains Stake – market - HPBL
Mirae Asset Global Investments Co. Ltd. Sells 74,818 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Shares of 10 Firms Soar on Friday - Insider Monkey
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.6%What's Next? - MarketBeat
Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday? - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 8.6% HigherWhat's Next? - MarketBeat
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why - MSN
Best Mid Cap Stocks To Follow TodayFebruary 14th - MarketBeat
Why Recursion Pharmaceuticals Stock Is Soaring Today - MSN
Best Pharmaceutical Stocks To Watch NowFebruary 14th - MarketBeat
Cathie Wood Doubles Down on 3D Systems, Blade Air Mobility, and Recursion Pharmaceuticals: Key Moves for Ark Invest – market - HPBL
SoftBank Latest Moves: Major Stakes in PacBio, Recursion Pharmaceuticals and Better Home & Finance - HPBL
Recursion Pharmaceuticals (RXRX) Stock Soars 15.8%, Nvidia Confidence Boosts Investor Sentiment - HPBL
Recursion Pharmaceuticals Soars 15.8% Amid Nvidia Confidence Boost – market - HPBL
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Feb 05 '25 |
Sale |
7.68 |
20,000 |
153,600 |
1,273,156 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):